|
gptkbp:instanceOf
|
immunotherapy
cancer vaccine
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L03AX17
|
|
gptkbp:brand
|
gptkb:Provenge
|
|
gptkbp:CASNumber
|
339986-88-8
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Dendreon
|
|
gptkbp:form
|
autologous cellular immunotherapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sipuleucel-T
|
|
gptkbp:indication
|
metastatic castration-resistant prostate cancer
|
|
gptkbp:KEGGID
|
D08916
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
stimulates immune response against prostate cancer cells
|
|
gptkbp:notRecommendedFor
|
gptkb:women
children
|
|
gptkbp:prescribes
|
adult males
|
|
gptkbp:PubChem_CID
|
1201832
DB06405
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
chills
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
prostatic acid phosphatase
|
|
gptkbp:UNII
|
8LJ08V8A5V
|
|
gptkbp:usedFor
|
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:Dendreon_Pharmaceuticals
gptkb:Dendreon
|
|
gptkbp:bfsLayer
|
7
|